Patent application number | Description | Published |
20080227156 | NUCLEIC ACIDS ENCODING NEUTRALIZING GDF8 EPITOPE-BASED PEPTIDES AND FUSION PROTEINS - The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention. | 09-18-2008 |
20090191239 | RECOMBINANT INFECTIOUS LARYNGOTRACHEITIS VIRUS AND USES THEREOF - The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. | 07-30-2009 |
20090208522 | Neutralizing Epitope-Based Growth Enhancing Vaccine - The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided. | 08-20-2009 |
20090274724 | NOVEL RECOMBINANT AND MUTANT ADENOVIRUSES - The present invention provides novel viral vectors. In one embodiment, the present invention provides mutant and recombinant bovine adenoviruses having a deletion and/or insertion of DNA in the early gene region 4 (E4). In another embodiment, the present invention provides mutant and recombinant bovine adenovirus 1 viruses having a deletion and/or insertion of DNA in the early gene region 3 (E3). The present invention also contemplates the use of the viral vectors for vaccination, gene therapy or other applications as suitable. | 11-05-2009 |
20090311282 | NEUTRALIZING GDF8 EPITOPE-BASED GROWTH ENHANCING VACCINE - The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention. | 12-17-2009 |
20100008948 | RECOMBINANT HERPESVIRUS USEFUL IN VACCINE PRODUCTION - The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided. | 01-14-2010 |
20100166800 | RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE - The present invention discloses attenuated | 07-01-2010 |
20110008377 | FELINE CD80, FELINE CD86, FELINE CD28, AND FELINE CTLA-4 NUCLEIC ACID AND POLYPEPTIDES - The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a vaccine comprising an effective amount of polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention also provides vaccines which further comprise immunogens derived from pathogens. The invention provides for vaccines capable of enhancing an immune response. The invention also provides for vaccines capable of suppressing and immune response. | 01-13-2011 |
20110008389 | RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE - The present invention discloses attenuated | 01-13-2011 |
20130295133 | RECOMBINANT VIRUS EXPRESSING FOREIGN DNA ENCODING FELINE CD80, FELINE CD86, FELINE CD28, OR FELINE CTLA-4 AND USES THEREOF - The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropriate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline. The present invention also comprises recombinant viruses which are capable of suppressing an immune response in a feline. | 11-07-2013 |